Inovio Pharmaceuticals - Post Covid
Seite 1 von 1 Neuester Beitrag: 19.05.23 21:06 | ||||
Eröffnet am: | 27.09.22 12:57 | von: Fu Hu | Anzahl Beiträge: | 6 |
Neuester Beitrag: | 19.05.23 21:06 | von: influ | Leser gesamt: | 6.059 |
Forum: | Börse | Leser heute: | 3 | |
Bewertet mit: | ||||
Dazu kommt der Cost-Cut Plan von diesem Jahr der sich auch auf die Ausgaben auswirken sollte.
Preliminary data showed that INO-4201 was well tolerated and produced a strong immune response. This suggests that a booster dose of IN0-4201 has the potential to extend protection against Ebola and could be an important tool in future Ebola Virus Disease prevention.
INO-4201 is INOVIO's DNA vaccine targeting Zaire Ebola virus (ZEBOV) glycoprotein (GP), designed to prevent ZEBOV infection. INO-4201 encodes for a synthetic consensus antigen that encompasses ZEBOV genetic variability from various outbreak strains to broaden immune coverage for divergent ZEBOV virus variants.